Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study

Lambìase, Alessandro; Leonardi, Andrea; Deligianni, Velika; Sposato, Sabrina; Bombardieri, Stefano

doi:10.1016/j.jaci.2011.07.004

Cited by 49 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of earlier studies are compatible with our findings [2,30,43,45]. For instance, in a recent randomized controlled study, it was shown that topical 0.05 % cyclosporine was safe and effective for the long-term prevention of VKC relapses [44].…”

Section: Discussionsupporting

confidence: 92%

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC (Adv Clin Exp Med 2014, 23, 3, 455-461).

show abstract

Section: Discussionsupporting

confidence: 92%

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…In a double-masked, randomised controlled clinical trial (RCT) no difference in efficacy between CsA 2% and dexamethasone 0.1% was found in the treatment of limbal VKC in Africa, but CsA was less well tolerated 89. Using a lower dose, an Italian trial demonstrated an inferior efficacy of CsA (0.1%) compared with dexamethasone 0.15% 90. Chronic use of topical CsA 0.05% has been shown to be effective in preventing seasonal recurrences of VKC 90…”

Section: Treatmentmentioning

confidence: 99%

Vernal keratoconjunctivitis: an update

Smedt¹,

2012

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterised by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae. Although rare in temperate regions, it represents an important cause of hospital referral in many parts of Africa and Asia. Clinical and immunohistochemical studies suggest that IgE-dependent (type I allergic) and IgE-independent (type IV allergic) mechanisms are involved in the immunopathogenesis of VKC, in which various inflammatory cells, including different T cell subpopulations play an active role via a cascade of chemical mediators. Endocrine, genetic, neurogenic, environmental and socioeconomic risk factors have been identified. However, its aetiology and pathophysiology remain unclear. The clinical course of this disease is usually benign and self-limiting, but a minority of patients will face very debilitating and sight threatening complications. Topical corticosteroids are often used during flare-ups in combination with mast cell stabilizers as maintenance treatment for VKC. However this management is unsatisfactory in controlling severe cases and avoiding recurrences. Non-steroidal immune modulators such as ciclosporin A and tacrolimus are promising alternatives, but tolerance to these agents needs to be improved and production costs reduced. The purpose of this review is to give an update on its epidemiology, immunopathogenesis and management. EPIDEMIOLOGYVernal keratoconjunctivitis (VKC) is a bilateral, chronic, external ocular inflammatory disorder, mainly affecting patients in their first or second decade.1-3 Although it is a rare allergic disorder in temperate regions, in many parts of Africa, Latin America and Asia VKC represents an important cause for hospital attendance, ranging from 3% to 6% of patients of all ages, rising to 33% and 90% in children and adolescents.2 4-7 A population prevalence of 4% to 5% has been found among African children.3 8 In large European and Asian case series boys appear to be affected more than girls, but this sex distribution is not found uniformly in Africa, and becomes less obvious with age.

show abstract

“…Topical immunomodulatory agents such as topical cyclosporine A [32][33][34] and tacrolimus [18,35] have been recently introduced for the treatment of VKC to avoid the complications associated with the prolonged use of steroids. In a recent randomized controlled study [33] it was shown that topical 0.05 % cyclosporine was safe and effective for the long-term prevention of VKC relapses.…”

Section: Discussionmentioning

confidence: 99%

“…In a recent randomized controlled study [33] it was shown that topical 0.05 % cyclosporine was safe and effective for the long-term prevention of VKC relapses. However, the results of the study demonstrate an inferior efficacy of 0.1 % cyclosporine compared with 0.15 % dexamethasone for the treatment of signs and symptoms during acute relapses.…”

Section: Discussionmentioning

confidence: 99%

Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety

et al. 2012

View full text Add to dashboard Cite

show abstract

Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study

Cited by 49 publications

References 9 publications

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Vernal keratoconjunctivitis: an update

Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety

Contact Info

Product

Resources

About